太龍藥業(600222.SH)2019年度業績扭虧為盈至4571.19萬元
格隆匯3月27日丨太龍藥業(600222.SH)發佈2019年年度報告,實現營業收入13.12億元,同比增長9.79%;歸屬於上市公司股東的淨利潤4571.19萬元,去年同期則為淨虧損1.15億元;歸屬於上市公司股東的扣除非經常性損益的淨利潤2886.01萬元,去年同期則為淨虧損1.1995億元;基本每股收益0.0822元。
報告期內,藥品製劑業務實現營業收入3.61億元,同比增長49.11%;精選雙黃連合劑(無糖型)、丹蔘口服液、烏金口服液等作為新的產品組合,啟動新的目標市場,為公司的後續發展提供了強有力的支撐。中藥飲片業務實現銷售收入6.35億元,同比增長12.08%。藥品研發服務方面,報告期公司簽訂合同總額近5億元,實現營業收入2.24億元,同比增長19.07%。藥品藥材流通業務實現營業收入5028.88萬元,較上年同期下降68.99%。
公司2020年經營目標:營業收入可比增長率不低於10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.